PTGX (Protagonist Therapeutics) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PTGX Protagonist Therapeutics Inc PTGX
47 GF Score
Price $135.47
GF Value $69.63
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Protagonist Therapeutics Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

PTGX
47GF Score
Protagonist Therapeutics Inc PTGX
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Protagonist Therapeutics (PTGX) Overvalued in 2026?

Based on GuruFocus' analysis, Protagonist Therapeutics stock appears to be overvalued. The current stock price of $135.47 is trading 94.6% above its estimated GF Value™ of $69.63. GuruFocus considers Protagonist Therapeutics to be Significantly Overvalued.

Key valuation signals for PTGX:

  • Short Ratio:
  • GF Value™: $69.63 vs. price of $135.47 (94.6% above fair value)
  • GF Score™: 47/100 with 8 warning signs

No single metric tells the full story. See the PTGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Protagonist Therapeutics Business Description

Address 7707 Gateway Boulevard, Suite 140, Newark, CA, USA, 94560
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
47GF Score

Get the complete analysis for PTGX

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$135.47
Price
$69.63
GF Value